Login / Signup

Effectiveness and Safety of Balloon Pulmonary Angioplasty for the Treatment of Patients with Persistent Pulmonary Hypertension after Pulmonary Endarterectomy.

Nicolas M Maneiro MelonMaría Teresa VelazquezSergio Huertas NietoAgustin Albarran Gonzalez-TrevillaFernando Sarnago CebadaAlejandro Cruz-UtrillaWilliams HinojosaRicardo Aguilar ColindresMaria Melendo ViuMaria Jesus Lopez GudeRafael Morales RuizMarta Perez NuñezFernando Arribas YnsaurriagaPilar Escribano-Subias
Published in: Journal of clinical medicine (2023)
(1) Background: Pulmonary endarterectomy (PEA) is the "gold standard" treatment for operable patients with chronic thromboembolic pulmonary hypertension (CTEPH). Persistent pulmonary hypertension (PH) after PEA confers a worse prognosis. Balloon pulmonary angioplasty (BPA) could represent a useful therapy in this setting, but evidence about its effectiveness and safety in patients with previous PEA is limited. (2) Methods: A total of 14 patients with persistent PH after PEA were treated with BPA in a single PH center. Hemodynamic and clinical effects of BPA and complications of the procedure were retrospectively collected. (3) Results: After BPA, the mean pulmonary arterial pressure fell from 50.7 ± 15.3 mmHg to 38.0 ± 7.9 mmHg (25.0% decrease; 95% confidence interval (CI) 14.0-35.5%; p = 0.01). Pulmonary vascular resistances were reduced from 8.5 ± 3.6 WU to 5.3 ± 2.2 WU (37.6% decrease; 95% CI 18.8-56.5%; p = 0.01). WHO functional class was also improved with BPA. Severe BPA-related complications were infrequent and no periprocedural deaths were observed. (4) Conclusions: BPA is an effective and safe therapy for patients with CTEPH and persistent PH after PEA.
Keyphrases
  • pulmonary hypertension
  • pulmonary artery
  • pulmonary arterial hypertension
  • stem cells
  • atrial fibrillation
  • coronary artery disease
  • coronary artery bypass grafting
  • bone marrow
  • mesenchymal stem cells